Antibiotic injection growth slides Carbon penicillin down 9% YoY

Since 2011, when the state officially implemented the "Strictest Anti-Resistance Order in History" and the Measures for the Clinical Application of Antibacterial Drugs, the Anti-Resistance Order has been further refined and implemented. Urban community medical treatment to cancel injection clinics, restrictions on infusion policies have been introduced in various places, in the grade hospitals, township hospitals have been landing.
Health Planning Commission issued a March 2017 anti-tube notice, strengthened carbon penicillin antibacterial drugs and special use of antimicrobial drugs such as cyclocycline management, emphasizing that outpatients should not use special use grade antimicrobial drugs, after nearly a year of rectification activities, the domestic key cities public hospitals have begun to bear fruit. The author interprets the latest data published by Minernet in detail.Strengthened resistance, can not relax
carbon penicillin antibiotics (Pernam) is a class of atypical β-endamide antibiotics, introduced in the 1980s, characterized by: broad spectrum, strong, bacterial resistance has a low rate, but it also has many kinds of adverse reactions, serious can lead to white blood cell reduction, neutral granulocyte reduction and nervous system, muscle spasms, nervous disorders, tremors, muscle spasms or epilepsy. In the case of the gradual escalation of antibiotic use, it is not to be underestimated to curb the expanded use of permnam drugs.
years, with the implementation of the "national anti-resistance policy", the trend of the whole body with antimicrobial drugs has been effectively curbed. From 2012 to 2013, the market for antibiotic hospitals plummeted, making the growth rate more normal. In particular, the National Action Plan to Curb Bacterial Resistance (2016-2020), jointly issued by 14 departments, including the National Health and Planning Commission, has become a milestone in the implementation of comprehensive antibiotics at the national level.
According to Minenet data, in the first three quarters of 2017, the amount of carbon penicillin antimicrobial drugs used in public hospitals in key cities in China was RMB1,666 million, resulting in a forecast of RMB2.332 billion for the whole of 2017, an increase of 4.80 percent year-on-year and a decrease of 9 percentage points year-on-year. It can be seen that the 2017 anti-tube notification has achieved results.Carbon penicillin just needed, not indiscriminate use
So far, there are seven carbon penicillin drugs on the market worldwide, of which the unilateral drugs are Meropenan, Biapenan, Ertapenan, Donipenan and Tebpenanan 5 varieties, the compound preparations are aminine/western statin, Panipenan/bitamilon. Under the influence of the patent expire of the original drug compound and the generic drug market, sales in foreign markets have gone from peak to high.
. According to relevant data, the global TOP3 carbon penicillin pharmaceutical original brand drug market in 2016 was $1.008 billion, the same as the previous year, which brings new development opportunities for the generic drug market.
According to Mienet data, in 2016 the domestic public medical institutions carbon penicillin antibiotic drug market sales have exceeded 10 billion yuan, overall, imported varieties and domestic varieties have formed a two-way situation. However, under the 2017 anti-tube notice, the domestic public medical institutions carbon penicillin antibiotic drug market showed a depressed situation.Key city public hospital carbon penicillin TOP3
At present, China's urban public hospitals used anti-bacterial infection drugs are divided into 10 sub-categories, TOP5 category is cephalosporine monodramine antibiotics, carbon penicillin, cephalosporin compound preparations, compound semi-synthetic penicillin and quinosteroid drugs. There are only 6 varieties of carbon penicillin drugs listed in China, accounting for 13.96 percent of the market for anti-bacterial drugs. In 2017, key urban public hospitals carbon penicillin TOP3 varieties are more than 300 million yuan varieties, accounting for 95% of the market share of carbon penicillin antibiotics, but also domestic public medical institutions anti-bacterial infection drugs more than 2 billion yuan of large varieties.Mero permantan leading anti-bacterial infection market
Mero Pernam is a variety jointly developed by Japan's Family Friends and the United Kingdom ICI, in 1999 Melo Pernam entered the Chinese market, the commodity is called "Mepin". In 1998, the domestic Mero Pernam has been successfully developed. So far, a total of 10 domestic public hospitals in Melo Pernam, 1 import enterprise, 9 domestic and joint ventures, domestic and imported drugs to promote market development.
the first three quarters of 2017, the amount of drugs used in public hospitals in key cities in China was 896 million yuan, and the total amount of drugs used in 2017 is forecast to be 1.255 billion yuan, according to Minanet data. The growth rate was 9.41 per cent, and the growth rate of 9.41 per cent in 2017 was 10 percentage points lower than the growth rate of 19.77 per cent in 2016, constrained by the National Resistance Order and the 2017 Anti-Regulation Order.
, among the suppliers of Mero Penanan, a public hospital in key cities in China, The imported drug Meiping, originally studied by Family Friend of Japan, accounted for 42.83 percent, while domestic production accounted for 57.17 percent. Among them, Shenzhen's seafront "multi-energy" accounted for 28.35 percent, shima's European-Italian "China Noshurok" accounted for 10.15 percent, Haizheng Pfizer's "Hai Zhengmeit" accounted for 9.26 percent, Haikou Pharmaceutical's "Angeli" accounted for 5.35 percent.
sales of China's public medical institutions reached 4.630 billion yuan in 2016, up 13.88 percent from the previous year, according to Milnet data. Sales are expected to be around 5 billion yuan in 2017.is the first carbon penicillin
antibiotic developed by Mercadon, Inc. of the United States. In 1985, the FDA approved the official listing of amine-pernamanstatin. In 1991, the sodium statin entered the Chinese market, the commodity name "Tainen". At present, imported products by Merca East, South Korea JWPharmaceutical Corporation, Taiwan's Political Germany and Taiwan's Xindong Sheng Technology 4 sales, 5 domestic companies to obtain the preparation approval.
According to Milnet data, in the first three quarters of 2017, the amount of drug use in public hospitals in key cities in China was 467 million yuan, and the total amount of drug use in 2017 is forecast to be 654 million yuan, a growth rate of 4.09 percent, similar to the growth rate in 2016. Before 2006, amine-pernaman cestatin was the leader in the pernam drug market, and after 2006 it was the second-largest drug after Meropenan.
Among the suppliers of the key city public hospitals in 2017, Merca Dong's original drug "Thai energy" accounted for 83.86 percent, Haizheng Pfizer accounted for 10.01 percent, Zhuhai Federation accounted for 3.56 percent, Shenzhen beach accounted for 1.27 percent, South Korea Yongjin accounted for 0.35 percent, and other enterprises accounted for 0.95 percent. According to the intelligent version of Milnet data show that in 2016, China's public medical institutions sales of aamine-pernamsin statins exceeded 2.5 billion yuan, imported drugs and joint-venture drugs accounted for more than 95% of the main market, domestic drugs accounted for about 5%.the localization of bio-Apenan
with the listing of bioantibodies and small molecule-targeted drugs, the market for anti-tumor drugs has moved from a warm-up period to a warming phase. Biapenan is an injectable penicillin antibiotic developed in 1989 by Lederle of Japan and Cyanamide of the United States, and launched in Japan in 2002 under the name "Omegaei". In 2008, Syngenta Pharmaceuticals and Zhengda Tianqing Pharmaceuticals obtained approval for the production of beavenan powder needles. Zhengda Tianqing Pharmaceuticals than Apeinan merchandise named "Sky Book", the first sound Dongyuan Pharmaceutical products named "Anxin." In 2009, Shi Pharmaceutical Group' Zhongno Pharmaceuticals obtained approval for the production of preparations, the commodity is called "Noganan".
According to Minanet data, in the first three quarters of 2017, the domestic key urban public hospitals than the Abernan drug market of 225 million yuan, the total amount of drug use in 2017 is forecast to be 315 million yuan, down 4.41% from the previous year, compared with the growth rate of 16.65 percent in 2016, is one of the significant decline in drugs. Among them, Zhengda Sunny's "Sky Book" accounted for 59.10%, Nanjing's "Anxin" accounted for 39.96 percent, Stone Medicine's "Noganan" accounted for 0.87 percent, Shandong Luoxin accounted for 0.08 percent. It is forecast that domestic drug sales will exceed 2 billion yuan. conclusion
with the domestic "restriction order" policy has landed, the antibiotic market from all the way up through the slide into normal benign development. Carbon penicillin is the most resistant to anti-infection clinical drugs, commonly known as "the last line of defense of antibiotics", this class of drugs is difficult to develop, the most complex production process, with high added value, is a very profitable variety, reasonable and standardized use is of great significance.
At the same time, with the advent of a new class of anti-infector drugs, the rapid growth of the domestic pyridoxine antibiotics lynymphazole, cyclolipidide antibiotics datomycin, glycamine cyclocycline antibiotics and vancomycin glycotin antibiotics for kolanin market, will become a direct challenge to carbon penicillin drugs new products. (Mi Net)